Neurogen Corporation Earnings Conference Call (Q3 2009)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Nov 6 Calls Today's Calls

Call Details Neurogen Corporation Earnings Conference Call (Q3 2009) Fri, Nov 6, 2009, 8:30 am Eastern Listen to the archived event audio About Neurogen Corporation (NasdaqGM:NRGN) Neurogen Corporation engages in the development of new small molecule drugs for psychiatric and neurological disorders. The company’s clinical development programs include aplindore, which is in Phase II clinical trials for the treatment of Parkinson’s disease and restless legs syndrome; and MK 2295, a VR1 receptor antagonist that is in preclinical development for the treatment of pain and cough. It has a collaboration and licensing agreement with Merck Sharp & Dohme Limited to research, develop, and commercialize small molecule medicines that work by targeting the VR1 receptor; and a licensing agreement with Wyeth Pharmaceuticals to acquire worldwide rights to aplindore. The company was founded in 1987 and is based in Branford, Connecticut. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings